🔧 Filters
Try: author name · keyword phrase · DOI
Original Article
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i) are highly effective lipid-lowering agents that reduce low-density lipoprotein cholesterol (LDL-C) by enhancing LD
PCSK9PCSK9iLDL-CAlirocumabEvolocumabFamilial hypercholesterolaemia
Review Article
Atherosclerosis was found in humans who lived thousands years ago. Paleopathologist Marc Armand Ruffer (1859-1917) identified atherosclerotic plaques in the aorta as well as in several large arteries
AtheromaLipoproteinsLDL cholesterolAncient MedicineExperimental atherosclerosisMolecular Biology
Original Article
Background: Dyslipidemia, characterized by abnormal blood lipid levels, is a major risk factor for cardiovascular disease, contributing to an estimated 4.2 million deaths and disabilities globally. Th
CholesterolDyslipidemiaHDLLDLLipid ProfileTriglycerides
Original Article
Background: Although statins remain the cornerstone of lipid-lowering therapy, LDL-C targets are often not achieved with statin monotherapy. This study evaluated the effectiveness and tolerability of
Dyslipidemialow-density lipoprotein cholesterolrosuvastatinezetimibecombination therapyatherosclerotic cardiovascular disease.